ELVN logo

Enliven Therapeutics, Inc. Stock Price

NasdaqGS:ELVN Community·US$1.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ELVN Share Price Performance

US$20.49
-8.48 (-29.27%)
US$20.49
-8.48 (-29.27%)
Price US$20.49

ELVN Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
2 Rewards

Enliven Therapeutics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$100.2m

Other Expenses

-US$100.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-1.69
0%
0%
0%
View Full Analysis

About ELVN

Founded
n/a
Employees
63
CEO
Samuel Kintz
WebsiteView website
www.enliventherapeutics.com

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Recent ELVN News & Updates

Recent updates

No updates